{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:56Z","timestamp":1791910676348,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T00:00:00Z","timestamp":1404518400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2377-14-142","type":"journal-article","created":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T03:01:08Z","timestamp":1404529268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Quality of life in purely ocular myasthenia in Japan"],"prefix":"10.1186","volume":"14","author":[{"given":"Shigeaki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomihiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Nagane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Oji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,5]]},"reference":[{"key":"1057_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB: Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8: 475-490.","journal-title":"Lancet Neurol"},{"key":"1057_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0960-8966(00)00173-5","volume":"11","author":"A Evoli","year":"2001","unstructured":"Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P: Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord. 2001, 11: 208-216.","journal-title":"Neuromuscul Disord"},{"key":"1057_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","volume":"189","author":"HJ Kaminski","year":"2004","unstructured":"Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME: Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol. 2004, 189: 333-342.","journal-title":"Exp Neurol"},{"key":"1057_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M: Lifetime course of myasthenia gravis. Muscle Nerve. 2008, 37: 141-149.","journal-title":"Muscle Nerve"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever Jr","year":"1983","unstructured":"Bever CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP: Prognosis of ocular myasthenia. Ann Neurol. 1983, 14: 516-519.","journal-title":"Ann Neurol"},{"key":"1057_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J: Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997, 62: 156-162.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1057_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P: Development of generalized disease at 2\u2009years in patients with ocular myasthenia gravis. Arch Neurol. 2003, 60: 243-248.","journal-title":"Arch Neurol"},{"key":"1057_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J: Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003, 23: 251-255.","journal-title":"J Neuroophthalmol"},{"key":"1057_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM: The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004, 217: 131-133.","journal-title":"J Neurol Sci"},{"key":"1057_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","volume":"41","author":"JA Allen","year":"2010","unstructured":"Allen JA, Scala S, Jones HR: Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve. 2010, 41: 379-384.","journal-title":"Muscle Nerve"},{"key":"1057_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/ene.12057","volume":"20","author":"H Zach","year":"2013","unstructured":"Zach H, Cetin H, Hilger E, Paul A, Wuschitz B, Jung R, Auff E, Zimprich F: The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol. 2013, 20: 708-713.","journal-title":"Eur J Neurol"},{"key":"1057_CR12","first-page":"CD005081","volume":"2","author":"M Benatar","year":"2006","unstructured":"Benatar M, Kaminski H: Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 2006, 2: CD005081-","journal-title":"Cochrane Database Syst Rev"},{"key":"1057_CR13","doi-asserted-by":"crossref","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE: EFNS\/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. doi: 10.1111\/ene.12359","DOI":"10.1111\/ene.12359"},{"key":"1057_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000, 55: 16-23.","journal-title":"Neurology"},{"key":"1057_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","volume":"71","author":"MJ Bhanushali","year":"2008","unstructured":"Bhanushali MJ, Wuu J, Benatar M: Treatment of ocular symptoms in myasthenia gravis. Neurology. 2008, 71: 1335-1341.","journal-title":"Neurology"},{"key":"1057_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","volume":"230","author":"S Suzuki","year":"2011","unstructured":"Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N: Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol. 2011, 230: 148-152.","journal-title":"J Neuroimmunol"},{"key":"1057_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","volume":"46","author":"M Masuda","year":"2012","unstructured":"Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, Shimizu Y, Utsumi H, Fujihara K, Uchiyama S, Suzuki N: The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012, 46: 166-173.","journal-title":"Muscle Nerve"},{"key":"1057_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archneur.57.5.752","volume":"57","author":"HJ Kaminski","year":"2000","unstructured":"Kaminski HJ, Daroff RB: Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol. 2000, 57: 752-753.","journal-title":"Arch Neurol"},{"key":"1057_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/jnnp.68.2.214","volume":"68","author":"A Komiyama","year":"2000","unstructured":"Komiyama A, Arai H, Kijima M, Hirayama K: Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2000, 68: 214-217.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1057_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mus.22002","volume":"44","author":"Y Nagane","year":"2011","unstructured":"Nagane Y, Utsugisawa K, Suzuki S, Masuda M, Shimizu Y, Utsumi H, Uchiyama S, Suzuki N: Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle Nerve. 2011, 44: 41-44.","journal-title":"Muscle Nerve"},{"key":"1057_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000356793","volume":"71","author":"Y Shimizu","year":"2014","unstructured":"Shimizu Y, Suzuki S, Utsugisawa K, Imai T, Murai H, Nagane Y, Tsuda E, Nagasao T, Ogata H, Yazawa M, Suzuki K, Kishi K: Is Surgical Intervention Safe and Effective in the Treatment of Myasthenic Blepharoptosis? A Multicenter Survey in Japan. Eur Neurol. 2014, 71: 259-261.","journal-title":"Eur Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-14-142\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T11:47:49Z","timestamp":1548244069000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-14-142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,5]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-14-142","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,5]]},"assertion":[{"value":"14 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"142"}}